Research programme: cancer therapeutics - EPI Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - EPI Pharmaceuticals

Alternative Names: PG-11000 Series; PG-11093; PG-11100 Series; PG-11122; PG-11144; SL11217; SL11218; SL11231; SL11237

Latest Information Update: 14 Dec 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellgate
  • Developer EPI Pharmaceuticals
  • Class Naphthoquinones; Polyamines; Porphyrins; Quinones
  • Mechanism of Action Apoptosis stimulants; Cell division inhibitors; Histone deacetylase inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Dec 2011 Progen Pharmaceuticals completes EPI Pharmaceuticals formation and transfers the epigenetic and cell proliferation assets to EPI
  • 25 Feb 2011 Progen's cancer therapeutics are still at the preclinical stage for Cancer in Australia
  • 25 Feb 2011 Research programme: cancer therapeutics - Progen Pharmaceuticals is available for licensing as of 25 Feb 2011. http://www.progen.com.au
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top